Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing
schedules of cemiplimab given in combination with cisplatin and docetaxel induction
chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head ...
Age: 18 years - 66+
Gender: All
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, efficacy, PK and
pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will
consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Par...
Age: 18 - 99 years
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or
Metastatic Solid Tumors
Age: 18 years - 66+
Gender: All
Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma
The study consists of Safety Run-in and Phase 2 Cohorts.
The primary objectives of the safety run-in cohorts of this study are to evaluate the safety,
tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with
pembrolizumab + 5-fluoroura...
Age: 18 years - 66+
Gender: All
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab in combination with radiation therapy
or pembrolizumab alone compared to the usual approach (chemotherapy plus radiation therapy)
after surgery in treating patients with head and neck squamous cell carcinoma th...
Age: 18 - 79 years
Gender: All
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
The purpose of this research study is to investigate a shorter radiation treatment schedule
for head and neck cancers in patients 70 years of age and older.
Standard radiation treatment for head and neck patients normally requires that the patient
travel to the ...
Age: 70 years - 66+
Gender: All
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an
engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally
occurring human antibody. The safety, tolerability, PK, and biological activity of...
Age: 18 years - 66+
Gender: All
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
The primary objective of the study is to evaluate the clinical activity of neoadjuvant
cemiplimab therapy in patients with resectable Non-small cell lung cancer (NSCLC),
Hepatocellular carcinoma (HCC), and Head and neck squamous cell carcinoma (HNSCC) lesions, as
...
Age: 18 years - 66+
Gender: All
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squ...
Age: 18 years - 66+
Gender: All